Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 13 for:    Idarucizumab OR praxbind

Medical Need of OAC Reversal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03254147
Recruitment Status : Completed
First Posted : August 18, 2017
Results First Posted : March 4, 2019
Last Update Posted : March 4, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF

Condition or disease Intervention/treatment
Atrial Fibrillation Drug: warfarin Drug: dabigatran Drug: Apixaban Drug: Edoxaban Drug: Rivaroxaban

Detailed Description:
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF, the incidence rates of emergency surgery, major bleeding due to trauma, and major bleeding due to fracture, overall and stratified by age (<64, 65-74, >75). The secondary objective is to estimate the overall and age stratified incidence of cardiac tamponade and peri-cardiocentesis.

Layout table for study information
Study Type : Observational
Actual Enrollment : 53969 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)
Actual Study Start Date : October 15, 2017
Actual Primary Completion Date : October 30, 2017
Actual Study Completion Date : November 10, 2017


Group/Cohort Intervention/treatment
patients prescribed with Oral Anti-coagulants
warfarin and non-vitamin K dependent oral anti-coagulants
Drug: warfarin
warfarin

Drug: dabigatran
Non-vitamin K dependent oral anti-coagulants (NOACs)
Other Name: PRADAXA, PRAZAXA

Drug: Apixaban
Non-vitamin K dependent oral anti-coagulants (NOACs)

Drug: Edoxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)

Drug: Rivaroxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)




Primary Outcome Measures :
  1. The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. [ Time Frame: One year ]
    The number of patients with emergency surgery and major bleeding due to fracture or trauma. Where emergency surgery defined as any surgical procedure (International Classification of Diseases (ICD) 10 code K000-879) performed on the same day as hospital admission with additional claims, major bleeding due to fracture is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any fracture, and major bleeding due to trauma is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any trauma.


Secondary Outcome Measures :
  1. The Number of Patients With Cardiac Tamponade and Pericardiocentesis. [ Time Frame: One year ]
    The number of patients with cardiac tamponade and pericardiocentesis. Cardiac tamponade diagnosis (ICD 10 code 4200001) on the same or next day as catheter ablation or percutaneous coronary intervention (PCI), Pericardiocentesis (Medical Data Vision (MDV) procedure code 140010510) on the same or next day as catheter ablation or PCI.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patients with atrial fibrillation contained in the Medical Data Vision (MDV) database which is a Japanese, nationwide claims data containing approximately 16 million patients cumulatively. The data cut is between March 2011 to June 2016, and the patients in the MDV database are those who have visited DPC hospitals (diagnostic procedure combination, a lump-sum payment system based on disease diagnosis to be treated similar to Medicare/Medicaid in the USA) hospitals which provide acute in-patient, as well as outpatient care.
Criteria

Inclusion Criteria:

->18 year old non-valvular atrial fibrillation (NVAF) patients

  • Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin
  • Patients with confirmed date of initiation of OACs
  • Patients with a minimum of 6 months of enrolment data prior to index date
  • Has an index date between 14th of March 2011 to 30 June, 2016

Exclusion Criteria:

  • Patients receiving two or more oral anti-coagulants at the same time at index date
  • Patients with prescriptions of index treatment in the 6 months prior to index date
  • Patients without enrolment period of at least six month in the database

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03254147


Locations
Layout table for location information
Japan
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, Japan
Sponsors and Collaborators
Boehringer Ingelheim
  Study Documents (Full-Text)

Documents provided by Boehringer Ingelheim:

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT03254147     History of Changes
Other Study ID Numbers: 1321-0022
First Posted: August 18, 2017    Key Record Dates
Results First Posted: March 4, 2019
Last Update Posted: March 4, 2019
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Warfarin
Rivaroxaban
Dabigatran
Apixaban
Edoxaban
Anticoagulants
Coagulants
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action